Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lannett Company, Inc.

https://www.lannett.com/

Latest From Lannett Company, Inc.

Lannett Advances Its Insulin Glargine Biosimilar

As Lannett announced the submission of an IND with the FDA for the proposed insulin glargine biosimilar rival to Lantus that it is developing with HEC, the company set out key development and commercialization milestones for the product in 2022, 2023 and 2024.

Biosimilars Clinical Trials

Lannett To Close And Sell NY Liquids Plant As Part Of Restructuring Plans

Lannett is once again taking the axe to its operations in order to tighten its focus and save on costs, including the planned divestment of its liquids generics manufacturing facility in Carmel, NY.

Business Strategies Manufacturing

Lannett To Close And Sell NY Liquids Plant As Part Of Restructuring Plans

Lannett is once again taking the axe to its operations in order to tighten its focus and save on costs, including the planned divestment of its liquids generics manufacturing facility in Carmel, New York.

Commercial Companies

Lannett Delivers On Internal Pipeline With Mycophenolate Mofetil Launch

Lannett has launched its internally-developed generic mycophenolate mofetil 200mg/ml oral suspension in the US, highlighting a first-cycle FDA approval as evidence of its capabilities as well as pointing to limited competition on the rival to Roche’s CellCept.

Launches United States
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Other Names / Subsidiaries
    • Kremers Urban Pharmaceuticals, Cody Laboratories, Silarx Pharmaceuticals
UsernamePublicRestriction

Register